Canadian researchers have found that pregnant women who are overweight or obese are more than 10 times more likely than women of normal weight to have their second trimester fetal ultrasound screening recalled due to poor results. Worse yet, a second exam may not improve visualization but instead add only to cost and patient distress.
Canadian researchers have found that pregnant women who are overweight or obese are more than 10 times more likely than women of normal weight to have their second trimester fetal ultrasound screening recalled due to poor results. Worse yet, a second exam may not improve visualization but instead add only to cost and patient distress.
The World Health Organization has called obesity a global pandemic. About 15% of the world's population and roughly 66% of the U.S. population is either overweight or obese. About 20% of women of reproductive age in the U.S. fit this category, according to the Centers for Disease Control and Prevention.
Obesity is considered a clinical risk factor in obstetric practice that poses a particular challenge for the completion of the second trimester fetal ultrasound survey, said principal investigator Dr. Phyllis Glanc, an assistant professor of medical imaging at the University of Toronto.
"This is a hot-button topic, but we don't believe it has been well documented," she said.
Glanc and colleagues at the university's Sunnybrook Health Sciences Center retrospectively reviewed records from 100 consecutive women with a body mass index (BMI) ≥30 when they underwent a routine second trimester fetal anatomic survey. They matched each case with two pregnant women of normal weight (BMI 20 to 25) and similar gestational age as controls. Each obese woman and her corresponding matching control underwent scanning by the same staff and equipment within a period of four days.
The investigators found that most pregnant women with high BMI had incomplete or unsatisfactory exams and that more than one-quarter of them required additional ultrasound scans to complete their surveys. Glanc presented her group's results at the 2008 American Roentgen Ray Society meeting in Washington, DC.
Twenty-six percent of screenings in the study group (BMI ≥30) were considered incomplete and required another scan as compared with only 2.5% in the control group. Scan visibility was rated as either satisfactory, moderate, or poor in 28%, 46%, and 26%, respectively, of women in the study group. In comparison, 88.5% of scans in the control group were satisfactory, while only 8.5% and 3% of them rated as either moderate or poor, respectively. Average BMI in the study group was 35.7 (range 30 to 64.8)
The most common indications for recall were inability to visualize the fetus' heart (16%), facial profile (10%), and spine (6%) compared with heart (0.5%) and spine (1%) in controls. Almost two-thirds of recalled exams remained categorized as having suboptimal visualization. Two patients scheduled for a repeat examination were lost to follow-up.
Findings highlight the challenges facing physicians responsible for managing obese pregnant patients and the need to find ways to improve their assessment, according to Glanc.
"Recall may not be the way to get around the problem of visualization," she said.
For more information from the Diagnostic Imaging archives:
Screening tackles hidden cardiovascular disease in retired football pros
Obesity research widens dialogue
Hot nodes emerge in obese women
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Appealing Prior Authorization Denials: Can it be Effective for Emerging Technologies?
May 14th 2024While radiologists and other providers may be discouraged by insurer denials saying the use of a technological advance is “unproven and investigational,” 82 percent of appeals for prior authorization denials were approved in 2021.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.